Indium In-111 Pentetate Disodium — Active Pharmaceutical Ingredient

Indium In-111 Pentetate Disodium is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: INJECTABLE. Routes: INTRATHECAL.

This content is for informational purposes only. Always consult a healthcare professional.

Indium In-111 Pentetate Disodium (1 brand name, 1 dosage form, 1 route)

Available dosage forms: INJECTABLE.

Routes of administration: INTRATHECAL.

Brand Names

  • MPI INDIUM DTPA IN 111

Indications and Usage

Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.

Dosage and Administration

Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70 kg) is 18.5 MBq, 500 µCi. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Contraindications

None known.

Adverse Reactions

Aseptic meningitis and pyrogenic reactions have been rarely (less than 0.4%) observed following cisternography with Pentetate lndium Disodium In 111. One death has been reported to have occurred within 20 minutes following the administration of Pentetate Indium Disodium In 111 and appears to be drug related. In addition, two cases of septic meningitis have also been reported. There have also been reports of skin reactions and vomiting following administration of Pentetate lndium Disodium In 111. Relationship of the drug to these latter occurrences has not been established.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.